1Palatini P, Julius S. Pathophysiology of the association between increased heart rate and cardiovascular morbidity and mortality. Medicographia,2002,24(3):201-206.?A
2Singh BN, SignhN. What is the future of agents that specifically reduce heart rate. Medicographia,2002,24(3): 237-244.?A
3Palatini P, JuliusS. Heart rate and the cardiovascular risk. J Hypertens,1997,15(1):3-17.?A
4VilaineJ P, ThollonC, Villeneuve N ,et al. Procoralan, a new selective if current inhibitor. Eur Heart Joumal,2003,5(Suppl G): G26 - G35.?A
5Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow- up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol,2004,43(7): 1 201 - 1 208.?A
6CIBIS- Investigators and Committees. The cardiac insufficiency bisoprolol study Ⅱ(CIBIS- Ⅱ ):a randomized trial. Lancet, 1999,353(9 146):9-13.?A
7MERIT- HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heartfailure (MERIT- HF).Lancet,1999,353(9 167):2 001-2 007.?A
8Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS)study. Circulation,2002,106(17) :2 194 - 2 199.?A
9Zuanetti G, Mantini I, Hemandez- Bernal F,et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction:insights from the GISSI - 2 study. Eur Heart J, 1998,19(Suppl F): F19-F26.?A
10Gillman MW, Kannel WB,Belanger A,et al. Influence of heart rate on motality among persons with hypertension: the framinhan study. Am Heart J,1993,125 (4):1 148-1 154.?A
